Department of Urology, Marien Hospital Herne, University Hospital of the Ruhr University of Bochum, Herne, Germany.
Department of Urology, Vivantes Network for Health, Berlin, Germany.
Clin Genitourin Cancer. 2024 Oct;22(5):102164. doi: 10.1016/j.clgc.2024.102164. Epub 2024 Jul 17.
Different combination therapies using anti - PD-1 / PD-L1 or CTLA-4 immune checkpoint inhibition (ICI) are widely used in patients with metastatic renal cell carcinoma (mRCC). In the absents of established biomarkers, immune-related adverse events (irAEs) have been discussed as potential predictors of response.
In this retrospective cohort study, data of 134 patients with mRCC undergoing ICI treatment (Nivolumab, Ipilimumab and Nivolumab, Pembrolizumab and Axitinib or Avelumab and Axitinib) between 2015 and 2021 were analyzed. To examine the utility of irAEs as predictors of overall survival (OS) and progression-free survival (PFS), separate Kaplan-Meier analyses and Cox proportional regression analyses were applied. Landmark analysis was conducted after 12 weeks to reduce immortal time bias.
irAEs were observed in 85 patients (63.4%). Cutaneous (n = 52, 38.8%), endocrine (n = 33, 24.6%) and hepatic (n = 19, 14.2%) irAEs were most commonly observed. In Kaplan-Meier analysis, patients experiencing irAEs showed favorable median PFS (15 months, 95% CI, 9.91-20.09) compared to the non-irAE group (5 months, 95% CI, 3.56-6.44, P < .001). The median OS was 25 months (95% CI, 16.79-33.21) in the non-irAE group, while it was not reached in the irAE group (P = .002). In multivariable analysis, the presence of any irAE was associated with favorable PFS (HR 0.46 [95% CI, 0.26-0.82] P = .008) and OS (HR: 0.28 [95% CI, 0.12-0.63] P = .002), respectively. Landmark analysis after 12 weeks showed mixed results depending on the classification of the irAE group at the landmark time.
The presence of irAEs under ICI therapy in patients with mRCC is associated with better PFS and OS. Thus, manageable irAEs should not be cause for premature discontinuation of ICI therapy, as they seem to indicate favorable outcomes. Considering the time-dependent nature of irAEs is crucial estimating their value as predictive markers.
抗 PD-1/PD-L1 或 CTLA-4 免疫检查点抑制(ICI)的不同联合治疗方案广泛用于转移性肾细胞癌(mRCC)患者。在缺乏既定生物标志物的情况下,免疫相关不良事件(irAEs)已被讨论为潜在的反应预测因子。
在这项回顾性队列研究中,分析了 2015 年至 2021 年间接受 ICI 治疗(Nivolumab、Ipilimumab 和 Nivolumab、Pembrolizumab 和 Axitinib 或 Avelumab 和 Axitinib)的 134 例 mRCC 患者的数据。为了研究 irAEs 作为总生存期(OS)和无进展生存期(PFS)预测因子的效用,分别进行了 Kaplan-Meier 分析和 Cox 比例风险回归分析。进行了 12 周的 landmark 分析以减少无永生时间偏倚。
85 例患者(63.4%)出现 irAEs。最常见的 irAEs 为皮肤(n=52,38.8%)、内分泌(n=33,24.6%)和肝脏(n=19,14.2%)。在 Kaplan-Meier 分析中,与非 irAE 组(5 个月,95%CI,3.56-6.44,P<.001)相比,出现 irAEs 的患者的中位 PFS 更有利(15 个月,95%CI,9.91-20.09)。非 irAE 组的中位 OS 为 25 个月(95%CI,16.79-33.21),而 irAE 组未达到(P=.002)。在多变量分析中,任何 irAE 的存在均与有利的 PFS(HR 0.46 [95%CI,0.26-0.82],P=.008)和 OS(HR:0.28 [95%CI,0.12-0.63],P=.002)相关。12 周后的 landmark 分析结果因 landmark 时间时 irAE 组的分类而异。
mRCC 患者接受 ICI 治疗时出现 irAEs 与更好的 PFS 和 OS 相关。因此,不应因管理良好的 irAEs 而过早停止 ICI 治疗,因为它们似乎预示着良好的结局。考虑到 irAEs 的时间依赖性,估计其作为预测标志物的价值至关重要。